Alnylam Pharmaceuticals, Inc. (0HD2.L)
USD 238.1
(0.23%)
USD 238.1
(0.23%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -282.17 Million USD | 64.06% |
| 2022 | -785.07 Million USD | -10.78% |
| 2021 | -708.65 Million USD | 14.46% |
| 2020 | -828.43 Million USD | 11.81% |
| 2019 | -939.43 Million USD | -15.31% |
| 2018 | -814.67 Million USD | -62.91% |
| 2017 | -500.08 Million USD | -17.78% |
| 2016 | -424.58 Million USD | -43.44% |
| 2015 | -296 Million USD | -60.69% |
| 2014 | -184.21 Million USD | -98.2% |
| 2013 | -92.94 Million USD | -52.99% |
| 2012 | -60.74 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -76.9 Million USD | -258.2% |
| 2024 Q1 | -43.43 Million USD | 62.69% |
| 2024 Q2 | 48.61 Million USD | 211.92% |
| 2023 Q3 | 213.86 Million USD | 193.05% |
| 2023 Q4 | -116.4 Million USD | -154.43% |
| 2023 FY | -282.17 Million USD | 64.06% |
| 2023 Q1 | -149.8 Million USD | 20.57% |
| 2023 Q2 | -229.83 Million USD | -53.42% |
| 2022 Q3 | -258.04 Million USD | -34.62% |
| 2022 Q2 | -191.68 Million USD | -30.64% |
| 2022 FY | -785.07 Million USD | -10.78% |
| 2022 Q1 | -146.73 Million USD | 24.58% |
| 2022 Q4 | -188.61 Million USD | 26.91% |
| 2021 Q2 | -146.16 Million USD | 21.53% |
| 2021 Q4 | -194.56 Million USD | -7.09% |
| 2021 FY | -708.65 Million USD | 14.46% |
| 2021 Q1 | -186.25 Million USD | 4.1% |
| 2021 Q3 | -181.67 Million USD | -24.3% |
| 2020 Q4 | -194.22 Million USD | 13.76% |
| 2020 FY | -828.43 Million USD | 11.81% |
| 2020 Q3 | -225.19 Million USD | -13.25% |
| 2020 Q2 | -198.85 Million USD | 5.38% |
| 2020 Q1 | -210.15 Million USD | 29.49% |
| 2019 Q1 | -188.78 Million USD | 14.33% |
| 2019 FY | -939.43 Million USD | -15.31% |
| 2019 Q4 | -298.07 Million USD | -37.81% |
| 2019 Q3 | -216.29 Million USD | 8.45% |
| 2019 Q2 | -236.27 Million USD | -25.15% |
| 2018 Q2 | -192.35 Million USD | -30.49% |
| 2018 Q1 | -147.4 Million USD | -0.07% |
| 2018 FY | -814.67 Million USD | -62.91% |
| 2018 Q4 | -220.35 Million USD | 13.44% |
| 2018 Q3 | -254.55 Million USD | -32.34% |
| 2017 Q4 | -147.3 Million USD | -17.09% |
| 2017 FY | -500.08 Million USD | -17.78% |
| 2017 Q3 | -125.8 Million USD | -4.42% |
| 2017 Q2 | -120.47 Million USD | -13.11% |
| 2017 Q1 | -106.51 Million USD | 7.73% |
| 2016 Q1 | -110.02 Million USD | -18.93% |
| 2016 Q2 | -92.45 Million USD | 15.98% |
| 2016 Q4 | -115.43 Million USD | -8.21% |
| 2016 Q3 | -106.67 Million USD | -15.39% |
| 2016 FY | -424.58 Million USD | -43.44% |
| 2015 Q1 | -52.22 Million USD | -14.24% |
| 2015 FY | -296 Million USD | -60.69% |
| 2015 Q4 | -92.51 Million USD | -18.11% |
| 2015 Q3 | -78.33 Million USD | -7.38% |
| 2015 Q2 | -72.94 Million USD | -39.68% |
| 2014 Q4 | -45.71 Million USD | -1.13% |
| 2014 Q3 | -45.19 Million USD | 7.56% |
| 2014 Q2 | -48.89 Million USD | -10.1% |
| 2014 Q1 | -44.4 Million USD | -50.07% |
| 2014 FY | -184.21 Million USD | -98.2% |
| 2013 FY | -92.94 Million USD | -52.99% |
| 2013 Q4 | -29.59 Million USD | 8.2% |
| 2013 Q1 | -9.8 Million USD | 58.05% |
| 2013 Q2 | -21.31 Million USD | -117.38% |
| 2013 Q3 | -32.23 Million USD | -51.25% |
| 2012 FY | -60.74 Million USD | 0.0% |
| 2012 Q4 | -23.36 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 245.121% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -189.835% |
| Myriad Genetics, Inc. | -123.7 Million USD | -128.112% |
| Evolus, Inc. | -49.23 Million USD | -473.142% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 20.229% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 120.902% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 27.922% |
| uniQure N.V. | -282.87 Million USD | 0.246% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -406.089% |
| Atara Biotherapeutics, Inc. | -276 Million USD | -2.235% |
| bluebird bio, Inc. | -244.26 Million USD | -15.521% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -485.425% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 363.022% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -283.943% |
| Dynavax Technologies Corporation | -37.02 Million USD | -662.058% |
| Editas Medicine, Inc. | -169.18 Million USD | -66.789% |
| FibroGen, Inc. | -281.81 Million USD | -0.128% |
| Geron Corporation | -193.94 Million USD | -45.493% |
| Blueprint Medicines Corporation | -486.27 Million USD | 41.972% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 114.273% |
| Illumina, Inc. | -1.06 Billion USD | 73.604% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 38.732% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -620.698% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 212.465% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -132.252% |
| Adicet Bio, Inc. | -152.03 Million USD | -85.595% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | -5.358% |
| Insmed Incorporated | -709.62 Million USD | 60.236% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 45.24% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 125.952% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -531.73% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -5255.381% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 97.995% |
| Waters Corporation | 817.67 Million USD | 134.509% |
| Zoetis Inc. | 3.06 Billion USD | 109.194% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 104.114% |
| Biogen Inc. | 1.29 Billion USD | 121.759% |
| Sangamo Therapeutics, Inc. | -274 Million USD | -2.982% |
| Nektar Therapeutics | -137.42 Million USD | -105.33% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -179.861% |
| Perrigo Company plc | 151.9 Million USD | 285.764% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | -21.719% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -155.097% |
| Verastem, Inc. | -92.08 Million USD | -206.432% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 106.551% |
| Imunon, Inc. | -21.03 Million USD | -1241.746% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -525.98% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | -81.39% |
| Homology Medicines, Inc. | -48.25 Million USD | -484.758% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 106.972% |
| OPKO Health, Inc. | -157.02 Million USD | -79.705% |
| Exelixis, Inc. | 170.88 Million USD | 265.126% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 183.589% |
| TG Therapeutics, Inc. | 20.63 Million USD | 1467.591% |
| Incyte Corporation | 620.52 Million USD | 145.474% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 61.154% |